Ally Bridge Group’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-170,000
Closed -$4.5M – 47
2022
Q2
$4.5M Hold
170,000
– – 4.1% 10
2022
Q1
$5.95M Buy
+170,000
New +$4.96M 4.41% 9
2021
Q3
– Sell
-675,670
Closed -$17.3M – 36
2021
Q2
$17.3M Sell
675,670
-1,052,920
-61% -$15.1M 4.3% 8
2021
Q1
$23.7M Sell
1,728,590
-38,850
-2% -$568K 4.55% 4
2020
Q4
$29.3M Hold
1,767,440
– – 5.02% 5

Other funds holding CERE

Ally Bridge Group's CERE Position: Q3 2022 in Review

Ally Bridge Group sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2022, closing a stake of 170,000 shares — an estimated $4.5M sold.

Ally Bridge Group first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $29.3M in Q4 2020. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

  • Ally Bridge Group reported no remaining Cerevel Therapeutics Holdings position as of Q3 2022 after selling out during the quarter.
  • Ally Bridge Group sold 170,000 Cerevel Therapeutics Holdings shares in Q3 2022, an estimated $4.5M.
  • Ally Bridge Group first reported a position in Cerevel Therapeutics Holdings in Q4 2020 and held it in 5 quarters.
  • Ally Bridge Group's Cerevel Therapeutics Holdings position peaked at $29.3M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2022.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.